Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2013 by Fundação Pró Rim
Sponsor:
Information provided by (Responsible Party):
Luciane Mônica Deboni, Fundação Pró Rim
ClinicalTrials.gov Identifier:
NCT01927588
First received: August 20, 2013
Last updated: NA
Last verified: August 2013
History: No changes posted
  Purpose

CMV infection is common in transplant patients and can cause graft loss. CMV is a major factor in increasing morbidity, and post-transplant costs. The CMV infection is associated with many deleterious indirect effects including rejection, interstitial fibrosis and tubular atrophy, mortality. In addition to the potential for undesirable clinical outcomes associated with CMV, there is also a negative economic aspect. Patients who developed CMV events have been found to use significantly more inpatient and outpatient resources than patients without CMV disease. Universal prophylaxis is associated with high treatment cost and the potential for drug-related toxicity. It can be speculated that use of EVR may offer additional economic benefits in terms of decreased utilization associated with prevention of CMV disease, and reduce use of costly prophylaxis. Any efforts to reduce costs in renal transplants are very important and may have a great impact in total cost of a renal program. And the other hand, the clinical data suggest that EVR is associated with a decrease in CMV incidence compared to mycophenolic acid (MPA). CMV replication is dependent upon 1 ou 2 mTor pathways and in vitro studies support an association between mTor inhibitors and decreased CMV infection and disease. In cardiac transplantation, the use of EVR was associated with a lower incidence of CMV events. Some clinical trials data have also shown that use of EVR was associated with a lower incidence of CMV infection compared to MPA following renal transplantation. Brennan et al compared the incidence of CMV in three clinical trials using EVR versus MPA in De Novo renal transplants. They pooled for analysis the studies B201, B251 and A2309, all double-blind, randomized, parallel-groups that compared the incidence of freedom form and incidence of CMV between EVR groups and MPA groups. The results of this pooled analysis of over 2000 patients de novo renal transplant demonstrated that EVR was associated with a decrease in and delay in the time of onset of CMV events compared to MPA. Our hypothesis is that basiliximab in combination with low dose tacrolimus, everolimus and prednisone may result in comparable efficacy (BCAR) observed in patients receiving tacrolimus/mycophenolate/prednisone but with a better safety profile (CMV infection) and cost-effectiveness.


Condition Intervention Phase
Cytomegalovirus Infections
Drug: Everolimus+Tacrolimus+Prednisone
Drug: Mycophenolate+Tacrolimus+Prednisone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.

Resource links provided by NLM:


Further study details as provided by Fundação Pró Rim:

Primary Outcome Measures:
  • Cytomegalovirus (CMV) infection investigation [ Time Frame: one year ] [ Designated as safety issue: Yes ]
    Blood samples will be collected to perform antigenemia at baseline, 1 month, 3 months 6 months and 12 months after transplant to investigate CMV infection.


Secondary Outcome Measures:
  • Transplant biopsies [ Time Frame: One year ] [ Designated as safety issue: Yes ]
    At 1, 3, and 12 month, a renal biopsy will be performed. Conventional staining and polyoma virus and CD4d immunohistochemical staining will be done. Methods for immunohistochemical staining procedures will be briefly described: 1. paraffin blocks were deparaffinized in multiple xylene baths, and tissues rehydrated in sequentially graduated ethyl alcohol baths; 2. Sample are predigested in 0.05% protease for 10 min at 37ºC to increase antigenic binding availability; 3.0 after rinsing in Trisbuffered saline, test slides and appropriate positive and negative controls are processed in an automated stainer. Primary antibody NCL-JCBK is applied for 2 hours (or overnight) at 37ºC temperature; then, the secondary antibody (anti-mouse peroxidase antibody) for 30 minutes at 37ºC.

  • C4d method [ Time Frame: one year ] [ Designated as safety issue: Yes ]
    1. Tissue will be stained using standard procedures with monoclonal anti-C4d at 1:100 dilution. 2. Secondary anti-mouse FITC-conjungated antibody is applied at a concentration of 1:20; 3. Quantification of staining is recorded, using routine protocols, including pretreatment for 15 min in boiling citrate (pH 8.0), a primary antibody concentration of 1:20 or 1:40 (titered by antibody lot), and secondary goat anti-rabbit IgG antibody at 1:360 dilution. Detection is performed with streptavidin/horseradish peroxidase (Jackson ImmunoResearch) and developed with Stable DAB (Dako, Carpenteria, CA).

  • Polyoma identification [ Time Frame: One year ] [ Designated as safety issue: Yes ]
    Urine samples will be collected to perform Decoy cells research and real time PCR analysis. Q-PCR amplification reactions will be set up in a reaction volume of 50 µl using the TaqMan Universal PCR Master Mix (PE Biosystems), containing 10 µl of purified DNA, 200 and 400 nM of VPf and VPr, and 50 nM of TaqMan probe. Thermal cycling was initiated with a 2-min incubation at 50 °C, followed by a first denaturation step of 10 min at 95 °C and then 40 cycles of 95 °C for 15 s (denaturation) and 60 °C for 1min. Real-time PCR amplification data will be collected continuously and analysed with the Sequence Detection System.


Estimated Enrollment: 50
Study Start Date: August 2013
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus+Tacrolimus+Prednisone
Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
Drug: Everolimus+Tacrolimus+Prednisone
Certican, introduced at Day7 post transplant + TACreduced + Steroids.
Other Names:
  • Certican
  • Tacrolimus
  • Prednisone
Active Comparator: Mycophenolate+Tacrolimus+Prednisone
Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
Drug: Mycophenolate+Tacrolimus+Prednisone
Myfortic + Tacrolimus full + Steroids, as control arm.
Other Names:
  • Myfortic
  • Tacrolimus
  • Prednisone

Detailed Description:

Objectives:

Primary To investigate the effect of early use of EVL plus TAC dose reduced vs. MPS plus TAC full dose on CMV infection by antigenemia 12 month after transplantation in stable kidney transplant recipients.

Secondaries

To evaluate renal function by cGFR (MDRD) To evaluate the incidence of acute rejection and nephrotoxicity by protocol biopsies; To evaluate the incidence of poliomavirus, according to treatment group, by quantitative PCR the BKviremia in urine and biopsy sample.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary kidney transplants (living or deceased donors);

Exclusion Criteria:

  • Recipients of a second transplant;
  • Recipients of multiple organs transplants;
  • PRA > 50%;
  • Chronic liver failure;
  • Presence of uncontrolled hypercholesterolemia (≥ 250 mg/dL);
  • Or hypertriglyceridemia (≥ 300 mg/dL).
  • Leucocytes count < 1500 per microliter;
  • Platelets count < 75000 per microliter;
  • Proteinuria > 800mg/day;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01927588

Contacts
Contact: Luciane M Deboni, Doctor, PI +55 47 96094320 lmdeboni@terra.com.br
Contact: Karjan H Mazzoleni, Nurse, SC +55 47 99141713 karjanhelena@gmail.com

Sponsors and Collaborators
Fundação Pró Rim
Investigators
Principal Investigator: Luciane M. Deboni, Msc Fundação Pró Rim
  More Information

No publications provided

Responsible Party: Luciane Mônica Deboni, Principal Investigator, Fundação Pró Rim
ClinicalTrials.gov Identifier: NCT01927588     History of Changes
Other Study ID Numbers: CRAD001ABR29T, CRAD001ABR29T
Study First Received: August 20, 2013
Last Updated: August 20, 2013
Health Authority: Brazil: Ethics Committee
Brazil: Ministry of Health
Brazil: National Committee of Ethics in Research
Brazil: National Health Surveillance Agency

Keywords provided by Fundação Pró Rim:
Certican
Renal Transplant
Cytomegalovirus Infection

Additional relevant MeSH terms:
Cytomegalovirus Infections
Infection
Communicable Diseases
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Everolimus
Sirolimus
Tacrolimus
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 22, 2014